Package Leaflet: Information for the User
Olanzapine Teva-ratio 10 mg orodispersible tablets EFG
Olanzapine
Read the entire package leaflet carefully before you start taking this medicine, because it contains important information for you.
even if their symptoms are the same as yours.
Contents of the package leaflet:
Olanzapina Teva-ratio contains the active substance olanzapine. Olanzapina Teva-ratio belongs to a group of medicines called antipsychotics.
Olanzapina Teva-ratio is used to:
? treat a disease with symptoms such as hearing, seeing or feeling unreal things, mistaken beliefs, unusual suspiciousness and a tendency to withdraw. People suffering from these diseases may also feel depressed, anxious or tense.
? treat a disorder characterized by symptoms such as feeling euphoric, having excessive energy, a need to sleep much less than usual, talking very quickly with flight of ideas and, sometimes, considerable irritability. It is also a mood stabilizer that prevents the appearance of extreme variations in mood.
Do not take Olanzapina Teva-ratio:
? if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6). The allergic reaction may manifest as a rash, itching, swelling of the face or lips or difficulty breathing. If this happens to you, tell your doctor.
? if you have previously been diagnosed with eye problems such as certain types of glaucoma (increased pressure in the eye).
Warnings and precautions
Talk to your doctor or pharmacist before starting to take Olanzapina Teva-ratio.
? The use of olanzapine is not recommended in elderly patients with dementia, as it may have serious side effects.
? Medicines of this type may cause unusual movements, especially in the face or tongue. If this happens to you after taking Olanzapina, tell your doctor.
? In very rare cases, medicines of this type produce a combination of fever, rapid breathing, sweating, muscle stiffness and a state of confusion or drowsiness. If this happens to you, contact your doctor immediately.
? Weight gain has been observed in patients taking Olanzapina. You and your doctor should check your weight regularly. If necessary, your doctor can help you plan a diet or consider referring you to a nutritionist.
? High levels of sugar and fats (triglycerides and cholesterol) have been observed in the blood of patients taking Olanzapina. Your doctor should perform blood tests to control your blood sugar and fat levels before you start taking Olanzapina and regularly during treatment.
? If you or a family member have a history of blood clots, consult your doctor, as medicines of this type have been associated with the formation of blood clots.
If you suffer from any of the following diseases, tell your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or cerebral ischemia.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to check your blood pressure.
Children and adolescents
Patients under 18 years of age should not take Olanzapina Teva-ratio.
Other medicines and Olanzapina Teva-ratio
Only use other medicines at the same time as Olanzapina Teva-ratio if your doctor authorizes it. You may feel drowsy if you combine Olanzapina Teva-ratio with antidepressants or medicines for anxiety or to help you sleep (tranquilizers).
You should inform your doctor if you are taking fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic), as it may be necessary to modify your dose of Olanzapina Teva-ratio.
Tell your doctor or pharmacist if you are taking or have recently taken other medicines or may need to take another medicine. Inform your doctor especially if you are using:
Taking Olanzapina Teva-ratio with food, drinks and alcohol
Olanzapina Teva-ratio can be taken with or without food.
You should not drink alcohol if you have been given Olanzapina Teva-ratio, as the combination of Olanzapina Teva-ratio and alcohol may cause drowsiness.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or plan to become pregnant, consult your doctor before using this medicine.
Pregnancy
Newborns of mothers who have used Olanzapina Teva-ratio in the last trimester of pregnancy may present with the following symptoms: tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing problems, and feeding problems. If your newborn presents with any of these symptoms, contact your doctor.
Breastfeeding
You should not take this medicine when you are breastfeeding, as small amounts of Olanzapina Teva-ratio may pass into breast milk.
Driving and using machines
Olanzapina Teva-ratio may cause symptoms such as drowsiness, dizziness or changes in vision, and reduce your reaction ability. These effects, as well as the disease itself, may make it difficult for you to drive vehicles or operate machines. Therefore, do not drive, operate machines, or engage in other activities that require special attention until your doctor assesses your response to this medicine.
Olanzapina Teva-ratio contains lactose and aspartame
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains 4.5 mg of aspartame in each tablet.
Aspartame contains a source of phenylalanine that may be harmful in case of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it properly.
Follow the instructions for administration of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
Your doctor will tell you how many Olanzapina Teva-ratio tablets you should take and for how long.
The daily dose of Olanzapina Teva-ratio ranges from 5 mg to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking Olanzapina Teva-ratio unless your doctor tells you to.
You should take your Olanzapina Teva-ratio tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. The tablets are for oral administration. Suck the tablets until they are completely dissolved in the mouth.
If you take more Olanzapina Teva-ratio than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
Patient who have taken more Olanzapina Teva-ratio than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue) and a reduced level of consciousness.
Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowing of respiratory rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms.
If you forget to take Olanzapina Teva-ratio
Take your tablet as soon as you remember. Do not take a double dose to make up for the forgotten dose.
If you stop taking Olanzapina Teva-ratio
If you suddenly stop taking Olanzapina Teva-ratio, you may experience symptoms such as sweating, insomnia, tremors, anxiety, nausea, or vomiting. Your doctor may suggest gradually reducing the dose before stopping treatment.
Do not interrupt treatment when you think you are feeling better. It is very important that you continue taking Olanzapina Teva-ratio while your doctor tells you to.
Patient under 18 years of age should not take Olanzapina Teva-ratio.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you have:
? Unusual movements (a frequent side effect that may affect up to 1 in 10 patients), especially of the face or tongue.
? Blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 patients), especially in the legs (symptoms include sweating, pain, and redness in the leg), which can travel through the blood to the lungs, causing chest pain and difficulty breathing. If you experience any of these symptoms, see a doctor immediately.
? A combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness (the frequency cannot be estimated from the available data).
Very common side effects: (may affect more than 1 in 10 patients)
? Weight gain.
? Drowsiness.
? Increased prolactin levels in the blood.
? In the early stages of treatment, some people experience dizziness or fainting (with slower heartbeats), especially when getting up from a lying or sitting position. This feeling usually disappears on its own, but if it does not, inform your doctor.
Common side effects: (may affect up to 1 in 10 patients)
? Changes in the levels of some blood cells, circulating lipids, and temporary increases in liver enzymes at the start of treatment.
? Increased blood sugar and urine levels.
? Increased uric acid, creatine phosphokinase, and alkaline phosphatase levels in the blood.
? Increased appetite.
? Dizziness.
? Agitation.
? Tremors.
? Abnormal movements (dyskinesia).
? Constipation.
? Dry mouth.
? Skin rash.
? Joint pain.
? Loss of strength.
? Excessive fatigue.
? Fluid retention that causes swelling of the hands, ankles, or feet.
? Fever.
? Sexual dysfunction such as decreased libido in men and women or erectile dysfunction in men.
Uncommon side effects: (may affect up to 1 in 100 patients)
? Hypersensitivity (e.g., inflammation of the mouth and throat, itching, skin rash).
? Diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in blood and urine) or coma.
? Seizures, in most cases related to a history of seizures (epilepsy).
? Muscle stiffness or spasms (including eye movements).
? Restless legs syndrome.
? Speech problems.
? Slow heartbeat.
? Abnormal heart rhythm.
? Sensitivity to sunlight.
? Nosebleeds.
? Blood clots such as deep vein thrombosis of the legs and blood clots in the lungs.
? Abdominal distension.
? Memory loss or forgetfulness.
? Urinary incontinence.
? Urinary retention.
? Difficulty urinating.
? Hair loss.
? Absence or decrease of menstrual periods.
? Changes in the breast in men and women, such as abnormal milk production or abnormal growth.
? Increased total bilirubin.
Rare side effects: (may affect up to 1 in 1000 patients)
? Decreased platelet count.
? Decrease in normal body temperature.
? Withdrawal syndrome when stopping treatment.
? Sudden unexplained death.
? Rapid heartbeat.
? Pancreatitis, which causes severe stomach pain, fever, and malaise.
? Liver disease, with yellowing of the skin and the white areas of the eyes.
? Muscle disorder that presents as unexplained pain.
? Prolonged and/or painful erection.
Side effects of unknown frequency (cannot be estimated from the available data)
? Withdrawal syndrome in newborns.
During treatment with olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, a rise in body temperature, redness of the skin, and walking problems.
A small increase in the number of deaths has been reported in elderly patients with dementia treated with antipsychotics, compared to those who do not receive this treatment.
Olanzapina Teva-ratio may worsen symptoms in patients with Parkinson's disease.
In rare cases, women who have been taking medicines of this type for a long time may secrete milk from the breast, stop having their monthly period, or have it irregularly. If this situation persists, consult your doctor. In very rare cases, babies of mothers who have taken Olanzapina Teva-ratio in the last stage of pregnancy (third trimester) may experience tremors, drowsiness, or lethargy.
Severe allergic reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. DRESS is initially manifested with symptoms similar to those of the flu, with a skin rash on the face that then spreads to other areas, fever, swelling of the lymph nodes, elevated liver enzyme levels in blood tests, and an increase in a type of white blood cell (eosinophilia).
Reporting of side effects:
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiry date stated on the packaging and blister after "EXP". The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Olanzapina Teva-ratio Composition:
Product Appearance and Packaging Content.
Olanzapina Teva-ratio 10 mg tablets are yellow, round, 10 mm in diameter.
Olanzapina Teva-ratio 10 mg is presented in tablet form. It is available in packs of 28 and 56 tablets.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder
Teva Pharma, S.L.U.
Anabel Segura 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108 Madrid (Spain)
Manufacturer:
Teva Pharma, S.L.U.
Polígono Malpica c/ C 4,
50016 Zaragoza.
Date of the Last Revision of this Prospectus:April 2020
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medication by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/73478/P_73478.html
The average price of OLANZAPINE TEVA-RATIO 10 mg ORALLY DISINTEGRATING TABLETS in October, 2025 is around 52.89 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.